Published on May 20, 2010 at 2:04 AM
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its subsidiary, Teva Canada received a Notice of Compliance from Health Canada to market its generic version of Pfizer's Lipitor® (atorvastatin) Tablets, a product indicated for lowering cholesterol. Shipment of this product will commence immediately.
Lipitor (atorvastatin) Tablets had annual brand sales of approximately C$1.3 billion in Canada.
SOURCE Teva Pharmaceutical Industries Ltd.